Scott P. Henry - Concepedia

Author

Scott P. Henry

Ionis Pharmaceuticals (United States)ORCID

Also Known As

Roger Lane, S P Henry, S. Henry, S. P. Henry, S.P. Henry, SCOTT P. HENRY, Scott Henry, Scott P Henry, Scott P. Henry, Theodore Schreiber

149

Publications

5.5K

Citations

H-Index

109

Concepts

All Affiliations

Ionis Pharmaceuticals (United States)University of Colorado Denver National Jewish Health Korea Institute of Toxicology

About

Scott P. Henry is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	32	1.9K
2	Allergy	8	8	600
3	Natural Sciences	5	5	447
4	Health Sciences	4	4	192
5	Public Health	1	1	24

Scott P. Henry

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Pharmacology of a Central Nervous System Delivered 2′-O-Methoxyethyl–Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates Frank Rigo, Seung Chun, Daniel A. Norris, Journal of Pharmacology and Experimental Therapeutics	2014	269
Activation of the Alternative Pathway of Complement by a Phosphorothioate Oligonucleotide: Potential Mechanism of Action Scott P. Henry, Patricia C. Giclas, Michael K. Pangburn, Journal of Pharmacology and Experimental Therapeutics	1997	203
An ICAM-1 Antisense Oligonucleotide Prevents and Reverses Dextran Sulfate Sodium-Induced Colitis in Mice C. Frank Bennett, Doug Kornbrust, Scott P. Henry, Journal of Pharmacology and Experimental Therapeutics	1997	191
Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts Sebastien A. Burel, Christopher E. Hart, Patrick Cauntay, Nucleic Acids Research ImmunologyMolecular BiologyLong Pre-mrna TranscriptsHigh Affinity ModificationsToxic Lna Asos	2015	191
PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES Richard S. Geary, Rosie Z. Yu, Tanya Watanabe, Drug Metabolism and Disposition	2003	162
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice Scott P. Henry, Kim Stecker, Doug A. Brooks, Journal of Pharmacology and Experimental Therapeutics	2000	146
Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide Scott P. Henry, Greg Beattie, Grace Chao Yeh, International Immunopharmacology Complement SystemPhosphorothioate OligodeoxynucleotideRhesus MonkeysMedicinePathogenesis	2002	143
Impurities in Oligonucleotide Drug Substances and Drug Products Daniel C. Capaldi, Andy Teasdale, Scott P. Henry, Nucleic Acid Therapeutics White PaperMolecular BiologyNucleic Acid ChemistryDrug PurityBioanalysis	2017	125
Inhibition of Coagulation by a Phosphorothioate Oligonucleotide Scott P. Henry, William Novotny, Carol S. Auletta, Antisense and Nucleic Acid Drug Development Translational MedicineBiochemistryPlasma OligonucleotideMedicinePhysiology	1997	124
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents. Monteith Dk, Scott P. Henry, Howard Rb, PubMed Autoimmune DiseaseAllergyImmune Cell DevelopmentMedicineImmune Regulation	1997	124

Page 1